Medidata Solutions Announces Enhanced Capabilities and Stand-Alone Option for Medidata Balance
Powerful Randomization and Supply Capabilities Can Now be Used Without Medidata Rave
NEW YORK--(BUSINESS WIRE)-- Medidata Solutions (NAS: MDSO) , a leading global provider of cloud-based clinical development solutions, announced that Medidata Balance™, the intelligent randomization and trial supply solution, is now being offered as a stand-alone system. This is a new alternative to the Balance solution that is unified with Medidata Rave®, the industry-leading electronic data capture (EDC), management and reporting system.
With powerful enhancements, including new trial supply capabilities and additional ways to conduct randomized trials, Balance introduces a new level of agility in randomization and supply management, whether used with or without Medidata Rave for electronic data collection.
As always, with Medidata Balance the need for software programming and extensive testing is eliminated. Balance brings together all elements of the design and execution of randomization and supply logistics plans into one simple solution operating out of the Medidata Clinical Cloud. The new version includes:
- A straightforward web interface guiding the creation of the randomization design and supply plans, including definition of complex dosing rules,
- A powerful dynamic allocation algorithm or permuted block method, now offering integrated list generation, that creates the assignments to arms and strata, and
- A groundbreaking integrated simulation tool testing the allocation of subjects and confirming the desired level of balance.
The new stand-alone version uses the same clean interface to deliver randomization and supply logistical information to study site staff. Additionally, the cloud-based solution offers site users a simple, intuitive web interface for screening, enrollment, randomization and kit dispensation.
"We continue to enhance the power and versatility of Medidata Balance to enable our customers to be more agile - to quickly adapt to changing needs and priorities, manage increased trial complexity and realize new efficiencies," said Glen de Vries, president, Medidata Solutions. "With the introduction of this new version of Balance, customers can create and execute trial randomization and supply plans within the pre-validated solution and without being restricted by EDC compatibility."
Connect with Medidata:
- Read our blog, Geeks Talk Clinical
- Tweet this: .@Medidata enhances #randomization and trial supply management solution Balance and adds stand-alone version #RTSM. http://bit.ly/TyiqCx
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
About Medidata Solutions
Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.
KEYWORDS: United States North America New York
The article Medidata Solutions Announces Enhanced Capabilities and Stand-Alone Option for Medidata Balance originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.